CryoLife (NYSE:CRY) Earning Somewhat Positive News Coverage, Analysis Shows

Media stories about CryoLife (NYSE:CRY) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. CryoLife earned a daily sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.3382814618325 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

CryoLife (NYSE CRY) traded down 0.25% on Friday, hitting $19.95. The stock had a trading volume of 79,135 shares. The company has a market cap of $667.25 million, a PE ratio of 60.45 and a beta of 0.92. CryoLife has a 12 month low of $14.03 and a 12 month high of $24.00. The company has a 50-day moving average of $21.90 and a 200 day moving average of $19.48.

CryoLife (NYSE:CRY) last issued its earnings results on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.10 by $0.02. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The firm had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $47.02 million. During the same quarter last year, the firm earned $0.13 earnings per share. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. On average, analysts predict that CryoLife will post $0.42 EPS for the current fiscal year.

CRY has been the subject of several research reports. Canaccord Genuity reiterated a “buy” rating and set a $25.00 price objective on shares of CryoLife in a research note on Monday, October 9th. Zacks Investment Research downgraded CryoLife from a “hold” rating to a “sell” rating in a research note on Tuesday, October 17th. Lake Street Capital boosted their price objective on CryoLife to $26.00 and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, BidaskClub downgraded CryoLife from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $23.63.

TRADEMARK VIOLATION WARNING: This report was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/cryolife-cry-earns-daily-news-sentiment-rating-of-0-13.html.

In other news, CEO James P. Mackin sold 125,000 shares of CryoLife stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $22.01, for a total transaction of $2,751,250.00. Following the sale, the chief executive officer now directly owns 398,399 shares of the company’s stock, valued at $8,768,761.99. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director James Benson sold 2,000 shares of CryoLife stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $22.80, for a total value of $45,600.00. The disclosure for this sale can be found here. Insiders sold 171,050 shares of company stock worth $3,769,825 over the last three months. 6.00% of the stock is currently owned by corporate insiders.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply